Head and Neck Squamous Cell Cancer Clinical Trial
Official title:
Head and Neck Cancer Screening and Serum Repository
Head and Neck Squaumous Cell Cancer(HNSCC) is the 6th most common cancer in the United States and the 3rd most common worldwide. Risk factors include abuse to tobacco and alcohol. Survival is related to stage of HNSCC when treatment is sought. Most HNSCC patients present with advanced staged disease. This screening activity will educate patients with HNSCC rick factors and screen for pre malignant and/or early staged lesions.
Otolaryngology staff memebers and residents will perform head and neck examinations upon participants after the participant has completed their questionnaire and had the opportunity to partcipate in the research portion by having blood drawn. A suspicious head and neck examination will be considered abnormal, and further recommendations for follow-up will be made. Participants will be provided with a list of practicing head and neck surgeons within the state of Arkansas. ;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03667482 -
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
|
Phase 1 | |
| Completed |
NCT02083692 -
Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling
|
Early Phase 1 | |
| Completed |
NCT02282371 -
Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
|
Phase 1 | |
| Active, not recruiting |
NCT03138070 -
A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719
|
N/A | |
| Active, not recruiting |
NCT02159508 -
Intensive Nutrition Counselling in Patients With Head and Neck Cancer
|
N/A | |
| Completed |
NCT02252042 -
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
|
Phase 3 | |
| Terminated |
NCT01790516 -
Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer
|
N/A | |
| Completed |
NCT00574977 -
Safety Study of Modified Vaccinia Virus to Cancer
|
Phase 1 | |
| Recruiting |
NCT02485548 -
Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer
|
Phase 3 | |
| Terminated |
NCT01326923 -
Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT03975270 -
Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma )
|
Phase 2 | |
| Terminated |
NCT04187872 -
LITT and Pembrolizumab in Recurrent Brain Metastasis
|
Phase 1 | |
| Recruiting |
NCT02327468 -
Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT01351103 -
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
|
Phase 1 | |
| Terminated |
NCT00260598 -
LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer
|
Phase 2 | |
| Completed |
NCT02163057 -
Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04856631 -
A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer
|
Phase 1/Phase 2 |